Stuart Arbuckle, who’s been with Vertex since 2012, plans to retire from his role in July. His departure comes as Vertex ...
In adults with cystic fibrosis, gastrointestinal symptoms initially improve with ETI but most do not consistently improve with longer-term use.
Vertex Pharmaceuticals Inc. will soon lose a member of its leadership team that helped the company achieve major revenue ...
Vertex Pharmaceuticals forecast annual revenue largely above Wall Street estimates on Monday, banking on robust sales of its ...
The FDA has granted priority review to brensocatib to treat patients with non-cystic fibrosis bronchiectasis, according to a ...
Background Early-life inflammation has long been recognised as a key pathophysiological process in the evolution of cystic ...
Two sizable companies and a handful of small Asian issuers were listed in the US this past week. Read more here.
Sionna Therapeutics SION) stock rises as the clinical-stage biopharma focused on cystic fibrosis therapies makes its public ...
Cystic-fibrosis-focused Sionna Therapeutics is joining the Nasdaq this morning with an upsized public offering, while obesity ...
Despite new medication, cystic fibrosis often leads to permanent lung damage. Working with an international team, researchers from the Technical University of Munich (TUM) have discovered that the ...
The biotech is evaluating several cystic fibrosis medicines that could either work alongside Vertex’s top-selling Trikafta or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback